Illumina, Inc.
ILMN
Rang in aandelen
#616
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Aandeelprijs
$262.32
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$39.61B
Verandering (1 dag)
-2.09%
Verandering (1 jaar)
174.80%
Land
US
Handel Illumina, Inc. (ILMN)
Categorie
Healthcare
EPS voor Illumina, Inc. (ILMN)
EPS per June 2026 TTM: $5.41
Volgens de laatste financiële rapporten en de aandelenkoers van Illumina, Inc. is de huidige EPS van het bedrijf (TTM) $5.41. Eind 2024 had het bedrijf een EPS van $-7.69, een stijging ten opzichte van de EPS van 2023 die $-7.35 bedroeg.
EPS-geschiedenis van Illumina, Inc. van 2000 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $5.41 | -1.10% |
| 2025 | $5.47 | -171.13% |
| 2024 | $-7.69 | 4.63% |
| 2023 | $-7.35 | -244.69% |
| 2022 | $5.08 | 13.90% |
| 2021 | $4.46 | -34.60% |
| 2019 | $6.82 | 21.35% |
| 2018 | $5.62 | 13.08% |
| 2017 | $4.97 | 57.78% |
| 2016 | $3.15 | -0.94% |
| 2015 | $3.18 | 21.84% |
| 2014 | $2.61 | 161.00% |
| 2013 | $1.00 | -18.70% |
| 2012 | $1.23 | 75.71% |
| 2011 | $0.70 | -30.69% |
| 2010 | $1.01 | 71.19% |
| 2009 | $0.59 | 37.21% |
| 2008 | $0.43 | -116.73% |
| 2007 | $-2.57 | -671.11% |
| 2006 | $0.45 | -273.08% |
| 2005 | $-0.26 | 199.54% |
| 2004 | $-0.09 | -79.33% |
| 2003 | $-0.42 | -35.38% |
| 2002 | $-0.65 | 54.76% |
| 2001 | $-0.42 | 27.27% |
| 2000 | $-0.33 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $18.62 | 244.18% |
US
|
|
| $5.65 | 4.44% |
US
|
|
| $-1.36 | -125.14% |
US
|
|
| - | - |
CN
|
|
| $5.09 | -5.91% |
US
|
